Our top pick for
Akorn Inc is a drug manufacturers-specialty & generic business based in the US. Akorn shares (AKRX) are listed on the NASDAQ and all prices are listed in US Dollars. Akorn employs 2,227 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.00 - $0.00|
|50-day moving average||$0.04|
|200-day moving average||$0.18|
|Wall St. target price||$2.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.82|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Akorn stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akorn's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Akorn's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $46.9 million.
The EBITDA is a measure of a Akorn's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$721.3 million|
|Gross profit TTM||$252.7 million|
|Return on assets TTM||-0.94%|
|Return on equity TTM||-231.8%|
|Market capitalisation||$12 million|
TTM: trailing 12 months
There are currently 11.9 million Akorn shares held short by investors – that's known as Akorn's "short interest". This figure is 10.9% up from 10.8 million last month.
There are a few different ways that this level of interest in shorting Akorn shares can be evaluated.
Akorn's "short interest ratio" (SIR) is the quantity of Akorn shares currently shorted divided by the average quantity of Akorn shares traded daily (recently around 24.3 million). Akorn's SIR currently stands at 0.49. In other words for every 100,000 Akorn shares traded daily on the market, roughly 490 shares are currently held short.
However Akorn's short interest can also be evaluated against the total number of Akorn shares, or, against the total number of tradable Akorn shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akorn's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Akorn shares in existence, roughly 90 shares are currently held short) or 0.1029% of the tradable shares (for every 100,000 tradable Akorn shares, roughly 103 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akorn.
Find out more about how you can short Akorn stock.
We're not expecting Akorn to pay a dividend over the next 12 months.
Over the last 12 months, Akorn's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akorn's is 1.1428. This would suggest that Akorn's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Akorn, Inc. , a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.